Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Total Current Liabilities: 2015-2024

Historic Total Current Liabilities for Spyre Therapeutics (SYRE) over the last 10 years, with Dec 2024 value amounting to $54.1 million.

  • Spyre Therapeutics' Total Current Liabilities fell 19.58% to $46.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $46.3 million, marking a year-over-year decrease of 19.58%. This contributed to the annual value of $54.1 million for FY2024, which is 69.05% up from last year.
  • As of FY2024, Spyre Therapeutics' Total Current Liabilities stood at $54.1 million, which was up 69.05% from $32.0 million recorded in FY2023.
  • In the past 5 years, Spyre Therapeutics' Total Current Liabilities registered a high of $54.1 million during FY2024, and its lowest value of $14.7 million during FY2022.
  • Its 3-year average for Total Current Liabilities is $33.6 million, with a median of $32.0 million in 2023.
  • In the last 5 years, Spyre Therapeutics' Total Current Liabilities declined by 27.24% in 2022 and then surged by 118.19% in 2023.
  • Over the past 5 years, Spyre Therapeutics' Total Current Liabilities (Yearly) stood at $16.4 million in 2020, then increased by 22.51% to $20.1 million in 2021, then fell by 27.24% to $14.7 million in 2022, then skyrocketed by 118.19% to $32.0 million in 2023, then skyrocketed by 69.05% to $54.1 million in 2024.